- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02194751
Oncoquest-L Vaccine in Patients With Previously Untreated Stage III or IV, Asymptomatic, Non-bulky Follicular Lymphoma
April 7, 2021 updated by: XEME Biopharma Inc.
This Phase II trial studies the overall tumor response of vaccine therapy in patientswith previously untreated Stage III or IV, asymptomatic, non-bulky follicular lymphoma.
The vaccine contains an extract of the patient's own cancer cells and the immunostimulant protein, interleukin-2 (IL-2).
It is hoped that when injected under the skin, the vaccine will enable the patient's immune system to recognize and destroy the cancer cells.
The trial will also assess the safety of the vaccine, the time from vaccine treatment until the patient requires another type of anti-lymphoma treatment, progression-free survival, and the anti-tumor immune response.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Detailed Description
This is a single-arm open-label pilot Phase II study.
Following informed consent, eligible subjects will undergo excisional biopsy of a lymphoma-containing lymph node for diagnosis and for generation of the Oncoquest-L vaccine.
Patients will receive subcutaneous injections consisting of their autologous tumor-derived Oncoquest-L vaccine starting at approximately 4 to 8 weeks after the biopsy.
The first two doses will be given at a 2-week interval and the remaining 3 doses at monthly intervals.
Patients will be monitored for response by performing imaging studies at baseline and 1 month after the fifth vaccination (Week 19).
Additional imaging studies will be performed every 3 months for the first year and every 6 months during the second year until relapse or disease progression whichever occurs sooner.
Study Type
Interventional
Enrollment (Anticipated)
30
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Mittie Mitchell, RN
- Phone Number: 770-400-7194
- Email: Mittie.Mitchell@ctca-hope.com
Study Contact Backup
- Name: Karen Rados
- Phone Number: 770-400-6629
- Email: Karon.Rados@ctca-hope.com
Study Locations
-
-
Georgia
-
Newnan, Georgia, United States, 30265
- Southeastern Regional Medical Center at CTCA
-
Contact:
- Karen Rados
- Phone Number: 770-400-6629
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Follicular lymphoma (FL) grade 1, 2, or 3a diagnosed within 12 months of study enrollment
- Age ≥ 18 years
- Previously untreated Stage III or IV FL
- A single peripheral lymph node of at least 1 x 1 cm in size accessible for excisional biopsy
- Measurable or evaluable disease after obtaining tissue for vaccine production
- Performance status (ECOG) of 0 or 1
- Asymptomatic disease without B symptoms or severe pruritus
Low tumor burden as defined by the following criteria:
- Normal lactic dehydrogenase
- Largest tumor mass < 7 cm
- Involvement of < 3 nodal sites with a diameter ≥ 3 cm
- No clinically significant pleural effusion or ascites
- Spleen size of ≤ 16 cm by CT scan
- Circulating tumor cells < 5.0 x 109/L
- No clinically significant organ compression
Adequate hematopoietic parameters:
- Absolute neutrophil count ≥ 1.5 x 109/L
- Platelet count ≥ 100 x 109/L
- Hemoglobin ≥ 10 g/dL
- Serum creatinine ≤ 2 x upper limit of normal (ULN)
- Total bilirubin ≤ 2 x ULN unless considered secondary to Gilbert's syndrome. Aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase ≤ 2 x ULN
- Fertile patients must use effective contraception during and for 12 months after completion of therapy
- For fertile female patients, a negative pregnancy test result at enrollment
Exclusion Criteria:
- Active HIV, hepatitis B, hepatitis C or other active infectious process
- Pregnant or nursing women
- Patients with previous history of malignancy within the past 2 years except curatively treated squamous or basal cell carcinoma of the skin or curatively treated carcinoma in situ of the cervix.
- Any medical or psychiatric condition that in the opinion of the principal investigator would compromise the patient's ability to tolerate this treatment
- Concurrent treatment with immunosuppressive therapy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Oncoquest-L vaccine
Patients will receive a total of 5 single injections of Oncoquest-L; the first 2 doses administered will be separated by a 2-week interval and the remaining 3 doses will be administered each at 1-month intervals.
With each dose of Oncoquest-L vaccine, the vaccine will be administered subcutaneously at 2 different sites in the upper arms or upper legs, with alternation of the injection sites with each administration.
|
Patients will receive a total of 5 single administrations of Oncoquest-L; the first 2 doses administered will be separated by a 2-week interval and the remaining 3 doses will be administered each at 1-month intervals.
With each dose of Oncoquest-L vaccine, the vaccine will be administered subcutaneously at 2 different sites in the upper arms or upper legs, with alternation of the injection sites with each administration.
For each vaccination, a total of 1.0 mL of vaccine will be administered, divided into 2 subcutaneous injections of 0.5 mL each at 2 different injection sites.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall tumor response rate
Time Frame: Up to 2 years
|
Tumor measurements will be performed at enrollment (baseline); then, tumor measurements and response assessments will occur 4 weeks after the 5th vaccination.
Thereafter, tumor measurements and response assessments will occur every 3 months during the 1st year and then every 6 months during the 2nd year until relapse or disease progression, whichever occurs first.
|
Up to 2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assessment of complete and partial tumor response rates
Time Frame: Up to 2 years
|
Tumor measurements will be performed at enrollment (baseline); then, tumor measurements and response assessments will occur 4 weeks after the 5th vaccination.
Thereafter, tumor measurements and response assessments will occur every 3 months during the 1st year and then every 6 months during the 2nd year until relapse or disease progression, whichever occurs first.
|
Up to 2 years
|
Assessment of time until initiation of radiotherapy or systemic therapy
Time Frame: Up to 2 years
|
Up to 2 years
|
|
Safety evaluation will include frequency, severity, and relationship of adverse events to vaccination; vital signs (blood pressure, respiration, pulse, and temperature); and laboratory test results (including, hematology and clinical chemistry)
Time Frame: From the time of informed consent up to 2 years
|
Safety parameters (e.g., adverse events, vital signs, and laboratory test results) will be recorded from the time patient signs informed consent, at every clinic visit during study treatment, 4 weeks after the 5th vaccination, and thereafter every 3 months during the 1st year and then every 6 months during the 2nd year.
|
From the time of informed consent up to 2 years
|
Tests to measure tumor-specific antibody production and T cell and B cell responses to vaccination
Time Frame: From 8 weeks prior to the 1st vaccination to Week 19 following the 1st vaccination.
|
Antibody production will be reported as increased titers of antibodies, B cells will be expressed as % B cell populations, T cell responses will be expressed as increases of tumor-specific T cells and changes in expression and quantity of cytokines (proteins that indicate changes in the immune response).
Blood samples will be collected within 8 weeks prior to the 1st vaccination (baseline); within 7 days prior to the 5th vaccination; and 4 weeks after the 5th vaccination.
|
From 8 weeks prior to the 1st vaccination to Week 19 following the 1st vaccination.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Brion Randolph, MD, Southeastern Regional Medical Center at Cancer Treatment Centers of America
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
July 1, 2021
Primary Completion (Anticipated)
June 1, 2024
Study Completion (Anticipated)
June 1, 2026
Study Registration Dates
First Submitted
July 14, 2014
First Submitted That Met QC Criteria
July 16, 2014
First Posted (Estimate)
July 18, 2014
Study Record Updates
Last Update Posted (Actual)
April 8, 2021
Last Update Submitted That Met QC Criteria
April 7, 2021
Last Verified
July 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- X13-21008
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Follicular Lymphoma
-
Joseph TuscanoNational Cancer Institute (NCI); Genentech, Inc.; Pharmacyclics LLC.RecruitingAnn Arbor Stage II Follicular Lymphoma | Ann Arbor Stage III Follicular Lymphoma | Ann Arbor Stage IV Follicular Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular LymphomaUnited States
-
National Cancer Institute (NCI)TerminatedStage III Grade 1 Follicular Lymphoma | Stage III Grade 2 Follicular Lymphoma | Stage III Grade 3 Follicular Lymphoma | Stage IV Grade 1 Follicular Lymphoma | Stage IV Grade 2 Follicular Lymphoma | Stage IV Grade 3 Follicular LymphomaUnited States
-
National Cancer Institute (NCI)RecruitingRecurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular LymphomaUnited States
-
Memorial Sloan Kettering Cancer CenterFox Chase Cancer Center; Pharmacyclics LLC.TerminatedFollicular Lymphoma | Follicular Lymphoma, Grade 1 | Follicular Lymphoma, Grade 2 | Follicular Lymphoma Grade IIIaUnited States
-
Robert LowskyNational Cancer Institute (NCI); Janssen, LP; The Leukemia and Lymphoma Society; Rising Tide FoundationCompletedMantle Cell Lymphoma | Marginal Zone Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular LymphomaUnited States
-
Olivia Newton-John Cancer Research InstituteBristol-Myers Squibb; Barwon Health; Austin Health; Eastern Health; Fiona Stanley... and other collaboratorsRecruitingFollicular Lymphoma Stage II | Follicular Lymphoma Stage III | Follicular Lymphoma Stage IVAustralia
-
Fondazione Italiana Linfomi ONLUSCompletedFollicular Lymphoma, Grade 1 | Follicular Lymphoma, Grade 2 | Follicular Lymphoma Grade 3AItaly
-
Massachusetts General HospitalTG TherapeuticsActive, not recruitingLymphoma | Follicular Lymphoma | Marginal Zone Lymphoma | Follicular Lymphoma, Grade 1 | Follicular Lymphoma Grade IIIa | Marginal Zone B Cell Lymphoma | Follicular Lymphoma Grade 2United States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingGrade 3a Follicular Lymphoma | Ann Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann Arbor Stage III Grade 3 Follicular Lymphoma | Ann Arbor Stage...United States
-
National Cancer Institute (NCI)Celgene CorporationActive, not recruitingAnn Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma | Ann Arbor Stage II Grade 3 Non-Contiguous... and other conditionsUnited States
Clinical Trials on Oncoquest-L vaccine
-
XEME Biopharma Inc.National Cancer Institute (NCI)Active, not recruitingChronic Lymphocytic Leukemia (CLL)United States
-
GlaxoSmithKlineRecruitingMeasles; Mumps; Rubella; ChickenpoxUnited States
-
Jiangsu Province Centers for Disease Control and...Wuhan Institute of Biological Products Co., LtdCompletedHand, Foot and Mouth DiseaseChina
-
AVAX TechnologiesTerminatedNon-Small Cell Lung Cancer - Completely ResectableUnited States
-
Bahria UniversityUniversity of Karachi; Jinnah Postgraduate Medical Centre; Pakistan Navy Station...RecruitingHemodialysis ComplicationPakistan
-
Butantan InstituteUniversity of Sao Paulo; Hospital Universitario da USPCompleted
-
Institute of Medical Biology, Chinese Academy of...Jiangsu Province Centers for Disease Control and PreventionCompleted
-
Sanofi Pasteur, a Sanofi CompanyRecruitingHealthy Volunteers | Respiratory Syncytial Virus Infection | Human MetapneumovirusUnited States, Puerto Rico
-
Tianhong LiNational Cancer Institute (NCI); LabyRx Immunologic TherapeuticsRecruitingAdvanced Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Metastatic Adenocarcinoma | Advanced Adenocarcinoma | Recurrent AdenocarcinomaUnited States
-
University of ManitobaMicropharma LimitedCompleted